• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on biological therapy >The evolution of biomarkers in rheumatoid arthritis: from clinical research to clinical care.
【24h】

The evolution of biomarkers in rheumatoid arthritis: from clinical research to clinical care.

机译：类风湿关节炎中生物标志物的演变：从临床研究到临床护理。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Treatment efficacy in rheumatoid arthritis (RA) has been measured by clinical response, gross radiological results and some biochemical markers. With the new biologic treatments, markers for disease development, progress, severity and therapy response have evolved. OBJECTIVES: This review focuses on a selection of current markers and the need for better markers for determining RA treatment susceptibility and success. METHODS: A review of the literature was conducted and expert opinions expressed. RESULTS/CONCLUSION: Current biomarkers mainly focus on disease activity and severity. Biomarkers for treatment response and susceptibility that help clinicians make initial treatment decisions are lacking or insufficient, yet required for optimal control of RA. A combination of biomarkers is necessary to classify a complex immune disease, such as RA.
机译：背景：类风湿关节炎（RA）的治疗效果已通过临床反应，总体放射学结果和一些生化指标进行了评估。随着新的生物治疗方法的发展，疾病发展，进展，严重程度和治疗反应的标志物已经发展起来。目的：本综述着重于选择当前的标志物以及确定更好的标志物来确定RA治疗的敏感性和成功性。方法：对文献进行回顾并发表专家意见。结果/结论：目前的生物标志物主要关注疾病的活动和严重程度。可以帮助临床医生做出初步治疗决策的治疗反应和药敏性生物标志物尚不足或不足，但仍需要最佳控制RA。生物标志物的组合对于分类复杂的免疫疾病（例如RA）是必不可少的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号